Core Viewpoint - The ongoing dispute between Hyaluronic Acid and recombinant collagen has gained significant attention, particularly involving major players in the medical aesthetics industry, Huaxi Biological and Juzhi Biological, leading to market volatility and investor caution [1][8]. Company Responses - Huaxi Biological expressed support for Dr. Hao Yu, emphasizing the importance of consumer rights and the integrity of product testing, while also indicating that they have conducted thorough evaluations of the claims made by Dr. Hao [2][5]. - Juzhi Biological issued a statement condemning Huaxi Biological's accusations as malicious and unfounded, highlighting their commitment to consumer trust and the integrity of their products [2][3]. Market Reaction - Following the controversy, Juzhi Biological's stock price fell over 5.6% on June 2, closing at 68.25 HKD per share, with a market capitalization of 731 billion HKD, reflecting investor concerns about the ongoing dispute [1][8]. Testing and Standards - The testing report that Dr. Hao Yu referenced was clarified by the testing agency, stating it was not legally valid for public proof and lacked comprehensive methodology, which raised questions about the reliability of the results [3][7]. - The lack of unified testing standards in the recombinant collagen industry has been highlighted as a significant issue, contributing to consumer distrust and regulatory challenges [7][9]. Industry Implications - The incident has exposed vulnerabilities in the regulatory framework and testing standards for the recombinant collagen sector, prompting discussions about the need for clearer guidelines and industry standards [7][9]. - The National Medical Products Administration has initiated the development of industry standards for recombinant collagen testing, indicating a move towards greater regulatory oversight [7].

Core Viewpoint - The ongoing controversy regarding the authenticity of collagen content in the "可复美胶原棒" product has sparked significant industry attention, with both 华熙生物 and 巨子生物 responding to the allegations made by 郝宇 and the testing institution involved [1][2]. Group 1: Company Responses - 华熙生物 issued a statement supporting 郝宇, indicating that they have conducted thorough evaluations and testing of the claims made against their products, and are willing to cooperate with regulatory bodies regarding the testing results [1]. - 巨子生物's 可复美 brand acknowledged the apology from the testing institution used by 郝宇 but stated their intention to pursue legal action against those spreading false information [2][3]. Group 2: Industry Implications - The dispute highlights the growing scrutiny within the medical aesthetics industry regarding product integrity and consumer trust, as both companies emphasize their commitment to transparency and consumer rights [2].

6月1日晚间，A股玻尿酸巨头华熙生物（688363）在微信号发表了一份逾2700字的长文支"大嘴博士"。 声明称，"华熙生物已组织专家对郝宇博士提供的资料进行审慎评估和多方法的反复测试，同时， 华熙生物也已经得到了第三方机构的检测结 果。 但在相关企业的自我检测结论公布之前，华熙生物出于对商业文明的最后一丝维护，希望相关企业主动面对发展中的问题，诚实面对全社 会关切的产品诚信和价值承诺。如监管机构需要查阅相关检测报告，华熙生物将毫无保留地配合提供；如相关企业无法正视自身问题，华熙生 物也将向全社会公开相关检测结果。" 声明中，华熙生物提及与郝宇博士的关系时表示，"鉴于热心网络水军的提醒，经过华熙生物核实，由郝宇博士担任法定代表人的上海柳页医 创医疗科技服务有限公司由华熙生物参与的海南海熙私募股权投资基金与郝宇博士相关公司共同投资，设立于2024年10月，华熙生物在该基金 中占比32.4%。基于此，由郝宇博士担任法人的柳页医创属于华熙生态的重要成员，华熙生物理应予以坚定支持和依法保护。" 华熙生物官方告诫这家擅长网络水军运营的公司："汝求战，便得战!"如果你们想要一个"商战"，那一定会得一个真正的商战。 医美龙 ...

Core Viewpoint - The article discusses the rise and challenges faced by Juzhi Biotechnology, highlighting its rapid growth in the beauty industry and the recent controversies surrounding its flagship product, the collagen stick. Group 1: Company Overview - Juzhi Biotechnology, founded by Yan Jianya and Fan Daidi, has become a significant player in the beauty industry, with a market value exceeding 450 billion yuan in May 2023, making them the richest couple in Shaanxi [1][2]. - The company specializes in recombinant collagen products, leveraging advanced biotechnology to create products that mimic human collagen [5][6]. Group 2: Recent Controversies - In May 2023, Juzhi Biotechnology faced backlash from competitors and influencers, particularly regarding the safety and authenticity of its collagen stick product [3][11]. - A beauty influencer claimed that the collagen stick contained only 0.0177% of the advertised recombinant collagen, significantly below the stated minimum of 0.1% [11][14]. - Juzhi Biotechnology responded by asserting that their products met industry standards and were undergoing third-party testing to verify their claims [14][16]. Group 3: Market Impact - Following the controversies, Juzhi Biotechnology's stock price dropped over 8%, reducing its market capitalization from 909 billion HKD to 735 billion HKD within ten days [3][19]. - The company has seen significant sales from its collagen stick, generating over 5.15 billion yuan in revenue since its launch, accounting for 82% of the company's total revenue in 2024 [16][19]. Group 4: Competitive Landscape - The article highlights the competitive tension between Juzhi Biotechnology and other industry players, particularly Huaxi Biological, which criticized Juzhi's marketing tactics and product claims [3][19]. - Both companies have invested heavily in marketing, with Juzhi's marketing expenses exceeding 2 billion yuan in 2024, while Huaxi's were around 24.64 billion yuan [19].

Core Viewpoint - The recent controversy surrounding hyaluronic acid and recombinant collagen products has led to significant scrutiny and volatility for leading companies in the medical beauty biotechnology sector, including Huaxi Biological, Juzhi Biological, and Jinbo Biological [2][11]. Group 1: Controversy and Market Reactions - Huaxi Biological publicly criticized brokerage reports for promoting the "hyaluronic acid is outdated" narrative, suggesting that the recombinant collagen concept is being overly hyped [3][11]. - Juzhi Biological faced public backlash due to a report indicating that its product "Kefumei" contained only 0.0177% recombinant collagen, below the legal threshold of 0.1% [4][11]. - Jinbo Biological's stock price was affected by the overall negative sentiment in the collagen sector, experiencing a significant drop of 17.23% from its peak [5][7]. Group 2: Financial Performance - Huaxi Biological reported its worst performance since going public in 2024, with revenue of 5.371 billion yuan, a year-on-year decrease of 11.61%, and a net profit of 174 million yuan, down 70.59% [9][10]. - Juzhi Biological achieved a revenue of 5.539 billion yuan in 2024, a year-on-year growth of 57.2%, but its core product's growth rate has been declining for four consecutive years [9][10]. - Jinbo Biological reported a revenue of 1.443 billion yuan in 2024, a year-on-year increase of 84.92%, but its growth rate has also shown signs of slowing down [10]. Group 3: Industry Dynamics - The ongoing "ingredient dispute" highlights the competition between hyaluronic acid and recombinant collagen technologies, with Huaxi Biological emphasizing the scientific value of hyaluronic acid [11][13]. - The controversy may intensify competition in technology development, market promotion, and brand building within the medical beauty industry, pushing for more emphasis on product efficacy and scientific validation [13].

Core Insights - The "颜值经济" (beauty economy) is thriving, with a growing preference for minimally invasive and immediate effect body shaping procedures, despite concerns over market information and effectiveness [2] - Meituan Medical Health launched the "放心美·无忧保障" (Worry-Free Beauty Assurance) service to address user concerns by providing a doctor-centered service model that ensures simple decision-making, transparent pricing, and guaranteed results [2] - The initial offering includes a fixed-price "V-face" plan with four key guarantees, and additional plans for other body parts will be introduced throughout the year [2] Group 1 - The "无忧保障" (Worry-Free Assurance) service is an upgrade to the "放心美" (Worry-Free Beauty) system launched in 2022, which has expanded to cover 2,000 medical beauty institutions and over 4,000 smart verification devices by the end of 2024 [3] - Meituan Medical Health aims to enhance the consumer experience in the medical beauty sector through collaboration with institutional partners, optimizing product and service processes [3] - The platform offers support to institutions participating in "无忧保障," including traffic allocation, exclusive assurance branding, and scene marketing, attracting 122 institutions across 12 cities [3]

Core Insights - The "beauty economy" is experiencing explosive growth driven by social media and consumer upgrades, with a particular rise in demand for minimally invasive body shaping procedures [1][3] - Meituan Medical Beauty has launched the "Worry-Free Beauty·No Worry Guarantee" service to address consumer concerns regarding decision-making and post-purchase experiences in the aesthetic medical sector [1][6] - The platform emphasizes a standardized service model that includes a transparent pricing structure and guarantees on the quality of medical professionals involved [1][4] Group 1: Service Offerings - The "Worry-Free Guarantee" includes a fixed-price model with four key consumer rights: adequate usage, no additional charges at the clinic, guaranteed operation by qualified doctors, and assurance against counterfeit drugs [1][6] - The initial offerings focus on facial procedures, with three pricing tiers (Light, Premium, Luxury) based on the materials used, sourced from reputable brands [6][7] - The platform has partnered with leading medical institutions to ensure that all services meet high standards of quality and safety [1][6] Group 2: Professional Ecosystem - The initiative aims to build a robust ecosystem for medical professionals, allowing them to focus on their expertise rather than marketing [3][4] - A dedicated information page for doctors will showcase their qualifications and patient reviews, enhancing transparency and trust [4][5] - The platform is also opening its content ecosystem to medical professionals, enabling them to share knowledge and experiences through user-generated content [4][5] Group 3: Market Impact - Approximately 40% of potential users express confusion over the plethora of marketing information available, indicating a significant market opportunity for standardized offerings [6][7] - The "Worry-Free Guarantee" is expected to streamline the decision-making process for consumers, reducing the time and effort required to choose services [7] - The initiative is part of a broader strategy to enhance consumer trust and satisfaction in the aesthetic medical industry, which is crucial for its sustainable growth [8]

Group 1 - A-shares experienced a significant rebound on Thursday, ending a period of low trading volume, driven by news of a U.S. court ruling that suspended the implementation of new tariffs announced by the Trump administration [1][3] - The market sentiment improved notably due to the court's decision, leading to a rise in U.S. stock index futures and a general increase in Asia-Pacific markets [1][3] - The future direction of tariff-related events remains uncertain, with potential implications for market performance depending on whether the Trump administration will appeal the ruling and how ongoing tariffs will be managed [1] Group 2 - June is expected to continue being driven by event-based thematic trading, with low-position sectors such as consumption and pharmaceuticals showing promise, alongside well-adjusted technology growth sectors [2] - The focus on expanding domestic consumption is a key task for 2025, with expectations for policy support to boost sectors like dairy products, IP consumption, leisure tourism, and medical aesthetics [2] - The trend towards domestic production of robotics is anticipated to grow, with opportunities arising in sensor, controller, and dexterous hand sectors as robots become more integrated into daily life [2] - The semiconductor industry is expected to continue its domestic production trend, with attention on semiconductor equipment, wafer manufacturing, materials, and IC design [2] - The military industry is projected to see a rebound in orders by 2025, with signs of recovery already visible in various sub-sectors [2] - The innovative pharmaceutical sector is entering a recovery phase after nearly four years of adjustment, with positive net profit growth expected to continue into 2025 [2]

Investment Rating - The report maintains a "Positive" outlook on international cosmetics and medical beauty companies for Q1 2025 [2]. Core Insights - The global beauty market is projected to grow at a rate of 4.5% in 2024, a decline from the 8% growth seen in 2023, with significant regional disparities [3][12]. - The North Asia market, particularly China, has shown signs of improvement, but overall performance remains subdued, with North America exhibiting signs of fatigue [3][12]. - International beauty groups are still grappling with performance declines or slower growth, which may become the new normal due to various factors including the pandemic and macroeconomic conditions [3][15]. - Companies are adopting localization strategies and investing in local brands to maintain market share amid fierce competition from domestic brands [3][19]. Summary by Sections 1. Global Beauty Market Trends - The beauty market continues a stable trend from 2024, with Europe outperforming other regions at a 7.5% growth, while North Asia has seen a 2% decline [3][12]. - The international beauty groups are facing a challenging environment with performance fluctuations and strategic adjustments [15]. 2. L'Oréal Performance - L'Oréal's Q1 2025 revenue growth slowed to 4.4%, with the Chinese market remaining flat and tourism retail channels under pressure [3][27]. - The company is actively investing in local brands and expanding its product matrix to compete with domestic brands [3][27]. 3. Estée Lauder Performance - Estée Lauder reported a 9.9% decline in revenue for Q1 2025, continuing a trend of three consecutive quarters of revenue decline [3][51]. - The company is undergoing strategic reforms to address issues related to brand and product positioning [47][51]. 4. Shiseido Performance - Shiseido's revenue decreased by 8.5% in Q1 2025, with its main brand struggling while the ELIXIR brand showed growth [3][18]. - The company is focusing on strategic product launches and price adjustments to enhance profitability [3][27]. 5. Investment Recommendations - Recommended companies include Up Beauty and Proya for their strong brand matrices and growth potential, as well as Marubi for leveraging Douyin traffic [4]. - In the medical beauty sector, companies with strong R&D capabilities and broad product pipelines, such as Aimeike, are highlighted as key investment opportunities [4].

Core Viewpoint - The event organized by SiYu MedTech aims to create a unique experience by enhancing information density and social efficiency within a three-hour timeframe, allowing participants to connect more deeply and learn extensively about the medical aesthetics technology landscape [1][2]. Product Flash Presentation - The event will feature a "Product Flash Presentation" segment where up to 20 technology companies can present their core value in a 3-minute pitch, covering various areas such as injection products, energy devices, postoperative recovery, and materials [2][3]. - This segment is designed to help attendees efficiently understand the current technological trends and developments in the medical aesthetics sector [2]. Group Social Interaction - A structured social interaction segment will be implemented, allowing participants to engage in multiple rounds of discussions, each lasting approximately 20 minutes, with different groups of attendees [6][7]. - The grouping mechanism will be determined by an algorithm based on the registration information, aiming to maximize networking opportunities and enhance social efficiency, potentially allowing participants to meet 60 to 80 professionals in just over an hour [9]. Free Networking - The event will conclude with a free networking session, providing attendees the opportunity to connect with others in the medical aesthetics industry, share ideas, and explore collaboration opportunities [10]. - Participants are encouraged to fill out registration forms accurately to facilitate effective grouping and networking [9]. Registration Information - Two types of registrations are available: for the "Product Flash Presentation" and for full attendance at the event, with a limit of 300 participants and an approval process in place [4][10]. - The event is scheduled for June 12, 2025, at the Beijing Zhongguancun Conference Center [10].